Clinical TrialDecember 1, 2024

TAME Trial Expansion: Metformin's Potential as Anti-Aging Drug

The Targeting Aging with Metformin (TAME) trial announces major expansion, adding new research centers and participants in this landmark study of aging intervention.

Expansion Highlights

Participant Growth

Participant pool expanded from 3,000 to 5,000 individuals, aged 65-79, providing more robust data for age-related outcomes.

New Centers

Addition of 12 new research centers across North America and Europe, bringing the total to 25 participating institutions.

Extended Duration

Study timeline extended to 8 years to capture long-term effects and age-related outcomes more comprehensively.

Enhanced Monitoring

Implementation of advanced biomarker tracking and cognitive assessment protocols across all centers.

About TAME Trial

The TAME (Targeting Aging with Metformin) trial is the first large-scale study designed to test whether a drug can slow the aging process and delay the onset of age-related diseases. Metformin, a widely-used diabetes medication, has shown promising potential in previous studies to influence multiple aging pathways.

This FDA-approved trial aims to establish aging itself as a treatable condition, potentially revolutionizing how we approach age-related diseases and longevity medicine.

Research Objectives

1.

Primary Endpoints

Measure the impact of metformin on the development of multiple age-related conditions simultaneously.

2.

Biomarker Analysis

Track comprehensive set of aging biomarkers to understand metformin's mechanisms of action.

3.

Quality of Life

Evaluate improvements in healthspan and functional capacity in the aging population.

Potential Impact

If successful, the TAME trial could:

  • Establish aging as an FDA-targetable indication
  • Create a pathway for testing other potential anti-aging compounds
  • Transform preventive medicine approaches
  • Lead to new therapeutic strategies for age-related diseases

The expansion of this trial represents a significant step forward in aging research and could accelerate the development of interventions that extend healthy human lifespan.

References

Stay Updated with Our Newsletter